Follow us on:

Linkedin Facebook

hVIVO release interim results on 10 September 2024, followed by analyst briefing

hVIVO plc

hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its interim results for the six months ended 30 June 2024 on Tuesday 10 September 2024.

Analyst briefing

A briefing open to equity research analysts will take place on Tuesday 10 September 2024 at 9.30am BST. To register and for more details please contact Walbrook PR on [email protected].

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

hVIVO

hVIVO signs new £2 million hMPV characterisation study contract

hVIVO plc secures a £2 million contract post-successful hMPV trial, advancing critical human challenge studies for future vaccine development.
Open Orphan

hVIVO reports positive results from RSV antiviral human challenge trial with Shionogi

hVIVO plc, a leader in human challenge clinical trials, reports successful Phase 2a results for Shionogi's RSV antiviral, S-337395, showing significant efficacy.
hVIVO

hVIVO and Inhalon Biopharma partner to test inhaled antiviral for RSV

hVIVO plc partners with Inhalon Biopharma to test IN-002, an inhaled antiviral for RSV, in a Phase 2a trial using their RSV Human Challenge Model.
hvivo plc

hVIVO plc Acquires two Clinical Research Units from CRS for €10.0m

hVIVO expands its clinical footprint by acquiring CRS, a German CRO, adding Phase I & II trial capabilities in Europe, enhancing strategic growth for 2025-2026.
hVIVO plc

hVIVO selected to conduct large-scale phase 3 Whooping Cough trial

hVIVO partners with ILiAD Biotechnologies for the first-ever Phase 3 human challenge trial of BPZE1, a next-gen Bordetella pertussis vaccine.
hVIVO plc

hVIVO Secures Landmark £3.2 Million Contract: Cavendish

hVIVO plc (LON:HVO) secures its largest £3.2M hLAB contract, expanding lab capacity and supporting a major Phase 2 study for a US biotech firm.

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.